aTyr Pharma (NASDAQ:LIFE) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

aTyr Pharma (NASDAQ:LIFE) posted its earnings results on Thursday. The biotechnology company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.01, Yahoo Finance reports. The firm had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.11 million.

aTyr Pharma Stock Up 0.6 %

Shares of NASDAQ:LIFE traded up $0.01 during trading hours on Friday, reaching $1.61. The stock had a trading volume of 258,232 shares, compared to its average volume of 367,840. aTyr Pharma has a 1 year low of $1.08 and a 1 year high of $2.70. The firm’s 50 day moving average is $1.77 and its 200-day moving average is $1.55. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.27 and a current ratio of 6.27. The stock has a market capitalization of $109.38 million, a price-to-earnings ratio of -1.79 and a beta of 1.27.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of aTyr Pharma in a report on Friday. Royal Bank of Canada reduced their target price on shares of aTyr Pharma from $19.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, March 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $23.67.

aTyr Pharma Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.